GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS)HIV Infections
- Interventions
- Drug: Background regimen
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT01923311
- Locations
- 🇿🇦
Be Part Yoluntu Centre, Cape Town, South Africa
🇮🇹Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01915472
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT01910636
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 323
- Registration Number
- NCT01909804
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
- Conditions
- HIV
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10577
- Registration Number
- NCT01906255
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
- Conditions
- HIV
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 172
- Registration Number
- NCT01902472
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 127
- Registration Number
- NCT01896193
- Locations
- 🇷🇺
Institute of Nutrition of Academy of Sciences, Moscow, Russian Federation
🇷🇺Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases, Saint-Petersburg, Russian Federation
🇷🇺Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department, Moscow, Russian Federation
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
- Conditions
- Limited SclerodermaDiffuse Scleroderma
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 29
- Registration Number
- NCT01881529
- Locations
- 🇦🇺
St Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
- Conditions
- Pre-exposure Prophylaxis for Prevention of HIV Infection
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 64186
- Registration Number
- NCT01865799
- Locations
- 🇺🇸
Gilead Sciences, Inc., Foster City, California, United States
A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication
- Conditions
- HIV Infection
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 99
- Registration Number
- NCT01865786
- Locations
- 🇺🇸
Antiretroviral Pregnancy Registry, Wilmington, North Carolina, United States